Keros Therapeutics
↗Lexington, Massachusetts, United States
Keros Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from rare hematological and musculoskeletal disorders with high unmet medical need. The company is a leader in understanding the transforming growth factor-beta (TGF-β) family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair, and maintenance of muscle and bone tissue. Founded in 2015 and publicly traded on NASDAQ, Keros has undergone significant strategic realignment in 2025-2026 to focus resources on its most promising pipeline candidates, particularly KER-065 (rinvatercept) for neuromuscular diseases.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Therapeutic Proteins and TGF-β Modulators
SIZE & FINANCIALS
Employees:101-200
Revenue:$247M
Founded:2015
Ownership:public
Status:operating
FUNDING
Stage:Public/Late Stage
Total Raised:$140M+
Investors:Public markets (IPO January 2024)
STOCK
Exchange:NASDAQ
Ticker:KROS
Market Cap:$464M
PIPELINE
Stage:Phase 1-3
Lead Drug Stage:Phase 2/3 (KER-050: Phase 3; KER-065: Phase 1-2)
Modalities:Protein therapeutics, ActRII ligand traps
Active Trials:3
Trial Phases:Phase 1: 1 | Phase 2: 1 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Takeda Pharmaceuticals - Global license agreement for elritercept (KER-050) outside mainland China/Hong Kong/Macau (December 2024), Hansoh (Shanghai) Healthtech - Development and commercialization of KER-050 in China, Massachusetts General Hospital/Sean M. Healey & AMG Center for ALS - Phase 2 trial collaboration for KER-065 in ALS (March 2026)
COMPETITION
Position:Emerging/Niche Player
Competitors:Protagonist Therapeutics, Crinetics Pharmaceuticals, Capricor Therapeutics, FibroGen, Jazz Pharmaceuticals, Recursion, Biogen, Dyne Therapeutics +3 more
LEADERSHIP
Key Executives:
Jasbir S. Seehra, Ph.D. - President, CEO, and Chair of Board
Lorena Lerner, Ph.D. - Chief Scientific Officer
Keith Regnante - Chief Financial Officer
Jean-Jacques Bienaimé - Chair of Board of Directors
Scientific Founders:Jasbir S. Seehra, Ph.D. (Founder)
Board Members:Jean-Jacques Bienaimé (Chair), Jasbir S. Seehra, Mary Ann Gray, Ph.D., Ran Nussbaum, Alpna Seth, Ph.D., Charles Newton (appointed March 2026)
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Keros Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Keros Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.